Dr David Lloyd
Medicinal organic chemist by training and holds the post of Hitachi Lecturer
in Advanced Computing in the Department of Biochemistry, Trinity College Dublin, where he heads Ireland's largest
computational drug discovery research group, working on rational design
projects funded by Science Foundation Ireland, the Health Research Board,
Enterprise Ireland and the Higher Education Authority.
Dr Lloyd previously held the post of Senior Scientist in the leading
Cambridge-based biotech startup, De Novo Pharmaceuticals, where he gained considerable experience in the
delivery of internal and external R&D projects, and headed the company's
ligand-based design technology development program.
Dr David LLoyd was Trinity College's Associate Dean of research (2005-2007) and he is currently Dean of Research for the University.
Professor Clive Williams
Professor of Biochemistry at Trinity College Dublin and the former Director
of the National Pharmaceutical Biotechnology Centre. Research within his
group has focused on the establishment of core assay technologies, with
receptor biology and design strategies based on his work in the area of
cell biology and in vitro screening. Prof Williams has over 100 publications in peer reviewed journals and
extensive experience of early stage commercialisation in the biotechnology sector.
Dr Darren Fayne
After completing his PhD in synthetic and computational chemistry in Dublin City University, Dr Darren Fayne worked for
2 years with the CADD Group in Solvay Pharmaceuticals, Hannover. He focused on two main therapeutic areas of research - Cardiovascular disease and Gastroenterology (IBS/IBD). Since July 2005 he has been managing the MDG, developing and
implementing research programmes around novel targets, validating targets and formulating lead optimisation strategies, acting
as the MDG financial controller and giving lectures to undergraduate/MSc/PhD students.
Dr Giorgio Carta
Since completing his PhD in Molecular Modelling in Trinity College Dublin, Giorgio has worked as a postdoctoral researcher in the Molecular Design Group - TCD. He focused his research mainly on nuclear receptors, specifically PPARgamma modulators and their role in CNS syndromes and diabetes. His key expertises include the development and application of computational tools to assist the drug discovery process, particularly in the area of hit to lead optimisation.